Methylprednisolone combined with azithromycin in treatment of children with refractory mycoplasma pneumonia

Abstract

Objective To explore the effect and safety of methylprednisolone combined with azithromycin in the treatment of children with refractory mycoplasma pneumonia. Methods 80 patients with refractory mycoplasma pneumonia treated at our hospital from November, 2014 to November, 2015 were selected and randomly divided into an experimental group and a conventional group, 40 cases for each group. Both groups generally used oxygen and were corrected acid-base balance disorder and supported with drugs and intravenously injected azithromycin aspartate. In addition, the experimental group were treated with methylprednisolone, 7 d as a course, for 3 courses. The body temperature recovery time, time treated at hospital, and the C-reactive protein levels when being admitted and after 1 treatment course were observed and recorded. Results The body temperature recovery time and time treated at hospital were shorter in the experimental group than in the conventional group, with statistical differences (P 0.05). During the treatment, one patient got facial flushing in the conventional group and the other patients occurred no adverse reactions. Conclusions Methylprednisolone combined with azithromycin in the treatment of children with refractory mycoplasma pneumonia can recover the patients’ body temperature in a short time and shorten consultation time and has no adverse reactions. Key words: Methylprednisolone; Azithromycin; Pediatric refractory mycoplasma pneumonia; Clinical efficacy; Safety analysis